Patents by Inventor Morrison Kendall

Morrison Kendall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
    Patent number: 12662532
    Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 23, 2026
    Assignee: TAE Life Sciences LLC
    Inventors: Sohye Kang, Morrison Kendall
  • Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
    Patent number: 12202893
    Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: January 21, 2025
    Assignee: TAE Life Sciences, LLC
    Inventors: Sohye Kang, Morrison Kendall
  • Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
    Publication number: 20240058466
    Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.
    Type: Application
    Filed: October 2, 2020
    Publication date: February 22, 2024
    Inventors: Sohye Kang, Morrison Kendall
  • Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof
    Publication number: 20230165967
    Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.
    Type: Application
    Filed: October 2, 2020
    Publication date: June 1, 2023
    Inventors: Sohye Kang, Morrison Kendall